drugset / Trial / NCT03981614
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Phase 2
Completed
102 enrolled
Academic and Community Cancer Research United
National Cancer Institute (NCI) · collab
RandomizedCrossoverOpen-labelTreatment
Summary
This phase II trial studies how well binimetinib and palbociclib work compared to TAS-102 in treating patients with KRAS and NRAS mutation positive colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving binimetinib and palbociclib may work better compared to TAS-102 alone in treating patients with colorectal cancer.
Timeline
- Start
- 2019-10-29
- Primary completion
- 2021-08-23
- Completion
- 2024-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | — | Oral |
| Subject | Palbociclib | Small molecule | — | Oral |
| Subject | Tipiracil | Small molecule | — | Oral |
| Subject | Trifluridine | Small molecule | — | Oral |